Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dimerix Limited ( (AU:DXB) ) has provided an update.
Dimerix Limited announced that all resolutions at its 2025 Annual General Meeting were passed with the required majorities. Key resolutions included the re-election of Dr. Sonia Poli as a director and the approval of a 10% placement capacity under ASX Listing Rule 7.1a. The successful passing of these resolutions supports Dimerix’s strategic initiatives and strengthens its governance structure, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs, particularly in the area of kidney disease.
Average Trading Volume: 1,198,023
Technical Sentiment Signal: Buy
Current Market Cap: A$288.2M
See more data about DXB stock on TipRanks’ Stock Analysis page.